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Abstract
Background: Ga-labeled radiotracers are increasingly used for PET imaging. During the labeling procedure, formation
of 68Ga-colloid may occur. Upon i.v. injection, 68Ga-colloid will accumulate rapidly in the liver, spleen, and bone
marrow, resulting in reduced target-to-background ratios. In this study, we applied a thin layer chromatography (TLC)
method to measure colloid content and we studied the effect of the purification method on the in vivo characteristics
of 68Ga-labeled DOTA-exendin-3.
DOTA-exendin-3 was labeled with 68Ga, and the colloid content was measured by TLC on silica gel ITLC with two
mobile phases. The labeling mixture was purified by gel filtration on a 5-ml G25M column, by reversed-phase high-
performance liquid chromatography (RP-HPLC) using a C8 column or by solid phase extraction (SPE) on an HLB
cartridge. The in vivo characteristics of the preparations were determined in BALB/c nude mice, and PET images were
acquired 1 h p.i. using a microPET scanner. In these studies, unpurified 68Ga-DOTA-exendin-3 and 111In-DOTA-
exendin-3 were used as a reference.
Results: The colloid content of 111In-DOTA-exendin-3 and unpurified, gel filtration, RP-HPLC- and SPE-purified
68Ga-DOTA exendin-3 was <3, 7, 9, <3, and <3 %, respectively. Unpurified 68Ga-DOTA exendin-3 showed high
liver and spleen uptake. Gel filtration partly removed 68Ga-colloid from the preparation, resulting in moderate
liver and spleen SPE-purified 68Ga-DOTA exendin-3 showed very low liver and spleen uptake, that was similar to
that of RP-HPLC purified 68Ga-DOTA exendin-3.
Conclusions: We showed that the colloid content can be measured by TLC and that solid phase extraction and
HPLC completely remove 68Ga-colloid from 68Ga-labeled tracer preparations, resulting in very low liver and spleen
uptake. This study clearly shows the importance of removal of 68Ga-colloid from preparations.
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Background
68Ga-labeled peptides are increasingly used for positron
emission tomography (PET), since 68Ga is a readily avail-
able PET radionuclide. Because 68Ga is a generator-
produced positron emitter, it is widely available and
relatively cheap. PET imaging is advantageous over
conventional scintigraphy and SPECT because of its
excellent sensitivity in combination with its superior
spatial resolution. A recent study in patients with
neuro-endocrine tumors (NET) showed that PET
imaging with the somatostatin analog 68Ga-DOTA-
TOC was more sensitive for detecting NET lesions than
conventional somatostatin receptor scintigraphy with
111In-octreotide [1]. Moreover, 68Ga-labeling of pep-
tides conjugated with a chelator (e.g., DOTA, NOTA) is
a fast and efficient one-step reaction. Because of all
these characteristics, there is an increasing interest in
the application of 68Ga-labeled peptides.
It has been shown that for efficient receptor targeting,
low peptide doses should be administered, since higher
peptide doses could lead to receptor saturation and
reduced uptake in the target tissue [2–5], especially in
preclinical imaging studies. In rodents, relatively high
activity doses (3–10 MBq) have to be administered to
acquire PET images with adequate image quality.
Therefore, 68Ga-labeled peptides with a high specific
activity should be produced to administer high activity
doses at a low amount of peptide. However, when pro-
ducing 68Ga-labeled compounds with a high specific
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activity, the formation of insoluble 68Ga-species, such
as 68Ga(OH)3 may occur. These insoluble
68Ga-species,
generally referred to as “68Ga-colloid” will accumulate
in the liver, spleen, and bone marrow. Indeed, previous
studies showed enhanced uptake in liver and spleen of
68Ga-labeled tracers as compared to the 111In-labeled
compounds [3, 6, 7]. This enhanced tracer uptake in
liver and spleen might result in decreased target-to-
background ratios. We previously showed that insoluble
68Ga-species can be removed from the labeling reaction
of 68Ga-labeled DOTA-exendin-3, a tracer targeting
the glucagon-like peptide-1 receptor (GLP-1R), using
(preparative) reversed-phase high-performance liquid
chromatography (RP-HPLC) [3]. However, this purifica-
tion method is time consuming and the solution of
purified 68Ga-labeled peptide is diluted, making post-
purification concentration necessary. Due to the short
half-life of 68Ga (68 min), this method is not convenient
in clinical practice. Moreover, purification with RP-
HPLC requires expensive equipment. Solid phase ex-
traction is an alternative method for purification of
radiolabeled compounds and is a fast, simple, and
cheap purification method that is now routinely used
for 68Ga-tracer purification [8, 9].
In this study, we examined the effect of the purification
method on the in vivo characteristics of 68Ga-DOTA-
exendin-3 in BALB/c nude mice. 68Ga-DOTA-exendin-3
was purified by RP-HPLC, gel filtration, or solid phase ex-
traction. Unpurified 68Ga-DOTA-exendin-3 and 111In-
DOTA-exendin-3 were used as a reference in this study.
In addition, we describe a quality control method, based
on instant thin layer chromatography (ITLC), to deter-
mine the colloid content of the 68Ga-labeled tracer [10].
Methods
Peptides and radionuclides
[Lys40(DOTA)]exendin-3 (DOTA-exendin-3) was pur-
chased from Peptide Specialty Laboratories (Heidelberg,
Germany). In this compound, DOTA (1,4,7,10-tetraaza-
cyclododecane-1,4,7,10-tetraacetic acid) is conjugated to
the ε-amino group of the lysine at position 40 (K40) and
the C-terminal carboxyl group is amidated [3]. 68GaCl3
was eluted from a TiO2-based 1110 MBq
68Ge/68Ga gen-
erator (IGG100, Eckert and Ziegler, Berlin, Germany)
with 0.1 N Ultrapure HCl (J.T. Baker, Deventer, The
Netherlands). 111InCl3 was obtained from Covidien
(Petten, The Netherlands).
Radiolabeling
DOTA-exendin-3 was labeled with 68Ga and 111In as
previously described [3]. Briefly, 120 MBq 68Ga in
1000 μl Ultrapure 0.1 N HCl was added to 10 μg
DOTA-exendin-3 in 120 μl 2.5 M HEPES (4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid, Sigma Aldrich,
St. Louis, MO, USA). After 20-min incubation at 95 °C,
EDTA was added to a final concentration of 5 mM and
the reaction mixture was incubated at room temperature
for another 5 min. Subsequently, 10 % Tween-80 (Sigma
Aldrich, St. Louis, MO, USA) was added to a final con-
centration of 0.1 % to prevent sticking of the radiola-
beled peptide to the vessel wall and quality control was
performed as described below.
DOTA-exendin-3 was labeled with 111In by adding
10 MBq 111InCl3 to 1 μg peptide in 0.1 M 2-(N-morpho-
lino)ethanesulfonic acid (MES), pH 5.5, under similar
conditions as described above.
Quality control
Quality control was performed using RP-HPLC on a C18
reversed-phase column (Zorbax Rx-C18; 4.6 mm ×
25 cm; Agilent Technologies, Palo Alto, CA, USA) and
instant thin layer chromatography (ITLC). The column
was eluted with mixture of water containing 0.1 % tri-
fluoroacetic acid (TFA) and acetonitrile with a linear
gradient from 3 to 100 % acetonitrile in 10 min (flow
rate 1 ml/min). ITLC was performed on silica gel ITLC
(Pall Corporation Life Sciences, New York, NY, USA).
Two mobile phases were used: 0.1 M EDTA in 0.25 M
NH4Ac, pH 5.5 (Rf = 0:
68Ga-labeled exendin and 68Ga-
colloid, Rf = 1:
68Ga-EDTA) and 1.25 M NH4Ac, pH 5.5:




Validation of the quality control by ITLC for the detection
of 68Ga-colloid
68Ga-colloid was prepared by adding 1250 μl 2.5 M
HEPES to 500 μl 68GaCl3 in 0.1 M HCl. The final pH of
this mixture was approximately 6. The mixture was in-
cubated at 95 °C for 15 min, and EDTA was added to a
final concentration of 5 mM. The amount of 68Ga-col-
loid was determined by TLC with 0.1 M EDTA in
0.25 M NH4Ac, pH 5.5 as a mobile phase (Rf = 0:
68Ga-
colloid, Rf = 1
68Ga-EDTA) and 1.25 M NH4Ac, pH 5.5:
DMF (1:1) as a mobile phase (Rf = 0:
68Ga-colloid, Rf = 1:
68Ga-EDTA). The reaction mixture was applied on a dis-
posable PD-10 desalting column, containing SephadexTM
G-25 medium (GE Life Sciences, Diegem, Belgium) and
was eluted with 6 ml phosphate-buffered saline (PBS)
containing 5 mM EDTA. The fraction containing the
majority of the radioactivity was collected (from 3–
4 ml), representing 68Ga-colloid, and quality control was
performed by ITLC as described above.
68Ga-DOTA-exendin-3 was purified by RP-HPLC as
described below, and various amounts of the 68Ga-col-
loid were added to obtain final 68Ga-colloid concentra-
tions of 1, 2, 3, 4, 5, 10, 20, 40, and 80 % (n = 4). The
amount of 68Ga-colloid was determined by ITLC with
1.25 M NH4Ac, pH 5.5: DMF (1:1) as the mobile phase
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(Rf = 0:
68Ga-colloid, Rf = 1:
68Ga-DOTA-exendin-3 and
68Ga-EDTA). RP-HPLC-purified 68Ga-DOTA-exendin-3,
68Ga-EDTA, and 68Ga-colloid were used as controls.
ITLC strips were exposed to an imaging plate (Fuji Film
BAS-SR 2025, Raytest, Straubenhardt, Germany) for
1 min. Images were acquired with a radioluminography
laser imager (Fuji Film BAS 1800 II system, Raytest,
Straubenhardt, Germany) and analyzed with Aida Image
Analyzer software (Raytest). Correlation between the
measured 68Ga-colloid fraction and the added 68Ga-col-
loid content was determined by linear regression using
GraphPad Prism 5. The detection limit of the ITLC
method was defined by the Y-intercept as determined by
linear regression analysis.
RP-HPLC purification of 68Ga-DOTA-exendin-3
After radiolabeling, the reaction mixture was purified by
HPLC, using a C8 reversed-phase column (Zorbax
eclipse XDB C8 4.6 mm × 150 mm, 5 μm, Agilent Tech-
nologies). The column was eluted with water containing
0.1 % TFA (0–5 min), 40 % ethanol (5–10 min) followed
by a linear gradient from 40 to 90 % ethanol in 5 min
(flow rate 1 ml/min). The fractions containing 68Ga-
DOTA-exendin-3 (retention time 14–15 min) were col-
lected and diluted with PBS containing 0.5 % bovine
serum albumin (BSA) to a final ethanol concentration of
less than 10 % before injection into mice (injection vol-
ume 0.2 ml). The radiochemical purity of the purified
68Ga-labeled DOTA-exendin-3 preparations was deter-
mined using ITLC as described above.
Purification of 68Ga-DOTA-exendin-3 by gel filtration
Purification by gel filtration was performed on dispos-
able PD-10 desalting columns, containing SephadexTM
G-25 medium (GE Life Sciences, Diegem, Belgium). The
column was preconditioned by eluting with 10 ml PBS
containing 0.5 % (v/w) BSA, and the reaction mixture was
loaded onto the column. The column was eluted with
PBS-BSA (0.5 %), and 0.5 ml fractions were collected. The
majority of the radioactivity, representing 68Ga-DOTA-
exendin-3, was collected in fractions 5 and 6 (2-3 ml). The
radiochemical purity of the tracer in the fractions was
analyzed by RP-HPLC and ITLC as described above.
Purification of 68Ga-DOTA-exendin-3 by solid phase
extraction
Solid phase extraction was performed using a hydrophilic-
lipophilic balance (HLB) reversed-phase sorbent cartridge
(Waters Oasis©, Milford, MA, USA). The cartridge was
activated by elution with 1 ml ethanol, the residual ethanol
was removed with 1 ml water (Versol, Lyon, France), and
the column was conditioned with 1 ml 0.1 N HCl:2.5 M
HEPES (8:1, similar to the reaction mixture). The reaction
mixture was loaded, and 68Ga-EDTA was washed from
the column with 2 ml 0.1 N HCl:2.5 M HEPES (8:1). After
removal of the residual HCl-HEPES mixture with 1 ml
water, 68Ga-DOTA-exendin-3 was eluted with 200 μl etha-
nol. The radiochemical purity of the tracer in the fractions
was analyzed by RP-HPLC and ITLC as described above.
Before injection into mice, the eluate containing 68Ga-
DOTA-exendin-3 was diluted with PBS containing 0.5 %
BSA to a final ethanol concentration of less than 10 %.
Biodistribution studies
Animal experiments were performed after approval of the
local ethical committee (RUDEC) for animal experiments.
The biodistribution of unpurified, gel filtration-, RP-HPLC-,
and SPE-purified 68Ga-DOTA-exendin-3 was determined
in BALB/c nude mice. Mice (n = 5) were injected intraven-
ously with 3 MBq 68Ga-labeled exendin-3 at a peptide
dose of 0.3 μg (60 pmol). As a control, another group of
mice received 370 kBq 111In-DTPA-exendin-3 (60 pmol).
The mice were euthanized 1 h post-injection by CO2/O2
suffocation, a blood sample was taken, and samples of
relevant tissues were dissected, weighed, and counted.
MicroPET
Mice were injected intravenously with 3 MBq (0.3 μg)
unpurified, gel filtratrion, RP-HPLC- or SPE-purified
68Ga-DOTA-exendin-3. Mice were euthanized 1 h p.i. by
CO2/O2 suffocation and PET images were acquired dur-
ing 45 min using a small-animal PET/CT scanner
(Inveon™; Preclinical Solutions, Siemens Medical Solu-
tions USA, Inc., Knoxville, TN, USA). Images were re-
constructed by OSEM3D/MAP reconstruction with the
following parameters: 256 × 256 matrix, 2 OSEM3D iter-
ations, 18 MAP iterations, and a resolution of 0.075 mm
uniform variance. CT images were acquired for anatom-
ical correlation directly after PET imaging (spatial reso-
lution 113 μm, 80 kV, 500 μA, exposure time 300 ms).
Statistical analysis
All mean values are expressed as mean ± standard devi-
ation (SD). Statistical analysis was performed using un-
paired two-tailed t test using GraphPad Prism (version
5). In order to determine whether there was a overall
difference in blood and kidney accumulation of the vari-
ous preparations, a one-way ANOVA was performed.
The level of significance was set at p < 0.05.
Results
Radiolabeling
DOTA-exendin-3 could be labeled with 68Ga with a spe-
cific activity of 110 GBq/μmol (at time of synthesis) with
a radiochemical purity >90 % (depending on the purifi-
cation method) after purification. The colloid content of
111In-DOTA-exendin-3 and unpurified, gel filtration,
RP-HPLC- and SPE-purified 68Ga-DOTA-exendin-3 was
Brom et al. EJNMMI Research  (2016) 6:65 Page 3 of 8
<3, 7, 9, <3, and <3 %, respectively (Table 1). Of note,
the initial colloid content of the labeling mixture varies,
which explains the higher colloid content of 68Ga-
DOTA-exendin-3 after gel filtration. After purification,
the percentage of unincorporated 68Ga was <3 % for all
preparations as determined by RP-HPLC.
Validation of TLC method
The results of the validation of the TLC method to
determine the colloid content in preparations of 68Ga-
DOTA-exendin-3 are shown in Fig. 1. The colloid con-
tent measured by TLC correlated linearly with the
amount of colloid present in the reaction mixtures (R2 =
0.98). The detection limit of the TLC method was a
68Ga-colloid content of 3.2 ± 0.9 %, as determined by the
Y-intercept of the trend line.
Biodistribution studies
The results of the biodistribution studies are summa-
rized in Fig. 2. 111In-DOTA-exendin-3 showed very low
accumulation in the liver and spleen: 0.7 ± 0.1 and 0.3 ±
0.1 %ID/g, respectively, representing the liver and spleen
uptake of a preparation without colloid. High uptake in
the liver and spleen (6.1 ± 1.0 and 4.5 ± 0.7 %ID, respect-
ively) was observed when unpurified 68Ga-DOTA-exen-
din-3 was injected. Gel filtration partially removed 68Ga-
hydroxide, resulting in intermediate uptake in the liver
and spleen: 3.0 ± 0.3 and 1.4 ± 0.3 %ID/g, respectively).
Uptake in the liver and spleen of SPE-purified (0.8 ± 0.0
%ID/g and 0.5 ± 0.1 %ID/g, respectively) and RP-HPLC-
purified tracer (0.6 ± 0.1 and 0.4 ± 0.1 %ID/g, respect-
ively) was very low and similar to liver and spleen uptake
of 111In-DOTA-exendin-3, indicating very efficient re-
moval of 68Ga-colloid with these purification methods.
The uptake in the pancreas was similar for all com-
pounds, except of RP-HPLC purified 68Ga-DOTA-exen-
din-3, that had a significantly higher pancreatic uptake
(10.2 ± 2.5 %ID/g, p < 0.05). A significant difference in
radioactivity concentration in the blood and kidneys
was found between all groups (p < 0.0001 and p =
0.0035 for blood and kidneys, respectively), probably
caused by differences in the colloid content of the vari-
ous preparations.
MicroPET
PET images of BALB/c nude mice after injection of
unpurified, gel filtration, RP-HPLC-, or SPE-purified
68Ga-DOTA-exendin-3 are shown in Fig. 3. With un-
purified 68Ga-DOTA-exendin-3, the liver was clearly
visualized in the PET images (Fig. 3a). Liver visualization
was less pronounced with 68Ga-DOTA-exendin-3 puri-
fied by gel filtration (Fig. 3b). No liver uptake was
visible when 68Ga-DOTA-exendin-3 was purified with
RP-HPLC (Fig. 3c) or SPE (Fig. 3d).
Discussion
During the radiolabeling procedure of DOTA-conjugated
compounds with 68Ga, in most cases, insoluble colloidal
68Ga species are formed, especially when compounds are
labeled at a high specific activity. This insoluble 68Ga-col-
loid results in enhanced accumulation in the liver and
spleen when injected in laboratory animals or patients,
resulting in reduced image quality. Therefore, prevention
of formation or removal of 68Ga-colloid is required. We
evaluated three purification methods for the removal of
68Ga-colloid: solid phase extraction (SPE), preparative
HPLC, and gel filtration. Solid phase extraction was a
fast and simple method that effectively removed 68Ga-
colloid from a labeling mixture of 68Ga-DOTA-exen-
din-3, resulting in negligible liver and spleen accumu-
lation similar to that of 111In-DOTA-exendin-3. The
major advantage of this technique is that purification
of the labeling mixture can be performed within 5 min.
Purification by preparative RP-HPLC resulted in simi-
lar spleen and liver accumulation. However, this tech-
nique is more time-consuming and less suited for
purification of 68Ga-labeled tracers, due to the short
half-life of 68Ga. Remarkably, the uptake of RP-HLPC-
purified 68Ga-DOTA-exendin-3 in the pancreas was
significantly higher. This is probably due to a slightly
lower peptide dose, which results in higher pancreatic
uptake as previously described [3]. Gel filtration re-
moved 68Ga-colloid less efficiently, resulting in higher
Table 1 68Ga-colloid content determined by ITLC, liver, and spleen uptake of unpurified, gel filtration, RP-HPLC- and SPE-purified
68Ga-DOTA-exendin-3 and 111In-DOTA-exendin-3 in BALB/c nude mice (n = 5 per group)
68Ga-colloid content (%) Liver uptake (% ID/g) Spleen uptake (% ID/g)
111In-DOTA-exendin-3 <3 0.7 ± 0.1 0.3 ± 0.1
68Ga-DOTA-exendin-3 7 6.1 ± 1.0 4.5 ± 0.7
Gel filtration purified
68Ga-DOTA-exendin-3
9 3.0 ± 0.3 1.4 ± 0.3
Solid phase extraction purified
68Ga-DOTA-exendin-3
<3 0.8 ± 0.0 0.5 ± 0.1
RP-HPLC purified
68Ga-DOTA-exendin-3
<3 0.6 ± 0.1 0.4 ± 0.1
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liver and spleen uptake than SPE and RP-HPLC purifica-
tion. It should be noted that gel filtration could be more
appropriate for the purification of larger compounds such
as proteins. The higher molecular weight of proteins
combined with the low molecular weight of 68Ga-colloid
could result in better separation. However, the feasibility
to separate 68Ga-colloid from high molecular weight
compounds by gel filtration should be evaluated.
High specific activities of 68Ga-labeled tracers are re-
quired to administer high activity doses in combination
with low peptide doses. It was shown that high peptide
doses lead to reduced uptake in the target tissues due to
(partly) saturation of the receptors [2–5], which is of
particular importance in preclinical imaging. Moreover,
high peptide doses can lead to (toxic) side effects, espe-
cially when biologically active compounds are used as
the ligand. The need for a high specific activity generally
enhances 68Ga-colloid formation, since incorporation of
68Ga present in the labeling mixture in the presence of
low amounts of metal binding ligand might be incom-
plete. Since 68Ga(OH)3 could be formed at pH 3 in the
absence of chelating agents (such as DOTA, DTPA, and
Fig. 1 ITLC method for determination of the 68Ga-colloid content. a TLC images and profiles of 68Ga-DOTA-exendin-3 with various amounts of
68Ga-colloid (typical examples). b Correlation between the amount of 68Ga-colloid added and the measured colloid content as determined by TLC
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EDTA) [11], 68Ga(OH)3 is formed in a labeling mixture at
a pH between 3.5 and 4 when 68Ga-incorporation is in-
complete. Interestingly, in the pH range generally used for
68Ga-labeling procedures (pH 3.5–4), Ga(III) is predomin-
antly present as polymeric Ga(III) hydroxides, while
Ga(OH)3 is the predominant form at pH 7 [12]. Further-
more, at higher pH, the formation of insoluble GaO(OH)
can occur [13]. GaO(OH) is particularly formed at high
temperature [14], which is of importance since most 68Ga-
labeling procedures are carried out at high temperatures
(80–100 °C). In contrast to Ga(III) hydroxides, GaO(OH)
is only slowly redissolved even at low pH [14].
Wild et al. showed a similar biodistribution of 68Ga-la-
beled DOTA-exendin-4 [15] as 68Ga-DOTA-exendin-3
Fig. 2 Biodistribution of unpurified, gel filtration, RP-HPLC and SPE-purified 68Ga-DOTA-exendin-3 in BALB/c nude mice (n = 5 per group). 111In-DOTA-
exendin-3 was used as a reference. Values are expressed as percentage of injected dose per gram of tissue (%ID/g) ± SD. Mice were dissected 1 h p.i
Fig. 3 PET images of BALB/c nude mice after injection of 3 MBq 68Ga-DOTA-exendin-3. PET was acquired 1 h p.i. after euthanasia with an acquisition
time of 45 min. High liver uptake is seen when the unpurified tracer is injected (a). Gel filtration partially removed the 68Ga-colloid (b), whereas no liver
uptake was observed when 68Ga-DOTA-exendin-3 was purified by RP-HPLC (c) or SPE (d)
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in our study. In the former study, no purification was
performed of the 68Ga-labeled compound, and this lead
to slightly higher uptake in the spleen as compared to
the SPE and RP-HPLC purified tracer used in our study.
However, the splenic uptake of 68Ga-DOTA-exendin-4
was lower than that of the unpurified 68Ga-DOTA-exen-
din-3 in our study. This lower uptake in the spleen of
68Ga-DOTA-exendin-4 reported by Wild et al. is prob-
ably due to a lower 68Ga-colloid content in the labeling
mixture. The lower 68Ga-colloid content might be due
to a lower specific activity of 68Ga-DOTA-exendin-4 and
a different labeling protocol. In the study performed by
Wild et al., the 68Ga-eluate was purified and the labeling
was performed in a microwave for 5 min. The shorter
labeling time in combination with the lower specific ac-
tivity may lead to faster and more complete incorpor-
ation of 68Ga, reducing the risk of 68Ga-colloid
formation [11]. Several other labeling methods [16, 17]
and chelators [18–21] for labeling compounds with
68Ga are described with more efficient labeling yields
and faster labeling kinetics. These new strategies for
68Ga-labeling of compounds might also reduce the risk
of 68Ga-colloid formation.
We validated a TLC method for the detection of 68Ga-
colloid in labeling mixtures of 68Ga-DOTA-exendin-3
and showed a clear linear correlation between added
68Ga-colloid to the labeling mixtures (free of 68Ga-col-
loid) and the measured 68Ga-colloid content. These re-
sults suggest accurate quantification of 68Ga-colloid in
the labeling mixture. Determination of the colloid con-
tent is of great importance to calculate the specific activ-
ity. Neglecting the presence of 68Ga-colloid might result
in overestimation of the specific activity and thus admin-
istration of a higher peptide dose as initially planned.
This is especially true for exendin, where very low pep-
tide doses need to be administered to prevent receptor
saturation resulting in lower uptake in GLP-1R-positive
tissues [3]. The detection limit of this method is ap-
proximately 3 % making detecting of very low concen-
trations of colloid difficult. The rather low sensitivity is
due to tailing of the radiolabeling peptide hampering the
clear delineation between the peak representing the
68Ga-colloid and the peak representing 68Ga-DOTA-
exendin-3. The sensitivity of this method for the deter-
mination of 68Ga-colloid for other peptides might be dif-
ferent due to different migratory characteristics of the
68Ga-peptide on this TLC system compared to exendin.
Enhanced liver and spleen uptake will hamper the de-
tection of lesions in the upper abdomen. Radiolabeled
exendin was successfully used for detection of insulino-
mas [22] and could potentially be used for detection of
the pancreatic beta cell mass. Enhanced liver and spleen
uptake might reduce the sensitivity of these methods.
Previous studies explored the feasibility of tumor
imaging and atherosclerotic plaques with 68GaCl3 in
mouse models for pancreatic adenocarcinoma and
artherosclerosis, respectively [23, 24]. Although the
tumor and atherosclerotic plaques could be detected, the
PET images suffered from high background signal in the
liver and lungs as well as high concentration in the
blood. The binding of 68Ga to transferrin (prolonging
the circulation time) and the formation of 68Ga-colloid
could explain the enhanced background and is in line
with our study.
Conclusions
Solid phase extraction using a HLB cartridge is a fast
and simple method to remove 68Ga-colloid. The uptake
in the liver and spleen of the SPE-purified product was
similar to that of 111In-DOTA-exendin-3 or HPLC-
purified 68Ga-DOTA-exendin-3, indicating sufficient re-
moval of insoluble 68Ga-colloid. Gel filtration only partly
removed 68Ga-colloid species and is not suitable for
purification of 68Ga-labeled exendin-3 and most likely
other peptides. Moreover, SPE cartridges are routinely
integrated in GMP-grade synthesis modules for 68Ga-la-
beling of peptide, and therefore, this method can be used
for purification of 68Ga-labeled compounds for human
use. Possibly, gel filtration might be suitable for larger
compounds (e.g., antibodies, proteins), since the per-
formance of size exclusion chromatography is expected
to be superior for larger compounds. However, the feasi-
bility for the removal of 68Ga-colloid by gel filtration of
proteins and compounds where solid phase extraction is
not possible should be verified. The studies presented
here show the importance of complete removal of 68Ga-
colloid before in vivo use.
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